Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$12.02 - $16.79 $961,600 - $1.34 Million
-80,000 Reduced 47.19%
89,539 $1.08 Million
Q4 2021

Feb 14, 2022

BUY
$9.93 - $15.39 $1.68 Million - $2.61 Million
169,539 New
169,539 $2.39 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Long Focus Capital Management, LLC Portfolio

Follow Long Focus Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.